Aegis Capital initiated coverage on Cingulate with a new price target
$CING
Biotechnology: Pharmaceutical Preparations
Health Care
Aegis Capital initiated coverage of Cingulate with a rating of Buy and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $12.00 | Buy | ROTH MKM |
| 12/22/2023 | Buy → Hold | Laidlaw | |
| 1/20/2022 | $8.50 | Buy | Laidlaw & Co. |
| 1/11/2022 | $9.00 | Buy | Aegis Capital |